BioSpace News Archive

Trefoil Therapeutics today announced the dosing of the first patient in its Phase 1 safety study evaluating TTHX1114.

Structure Therapeutics Inc. today announced the appointments of Eric Dobmeier and Joanne Waldstreicher, M.D., to its Board of Directors.

This week, the Association of Clinical Research Organizations (ACRO)’s RBQM Working Group published a paper in DIA’s Therapeutic Innovation & Regulatory Science journal titled, Risk-Based Monitoring in Clinical Trials: 2021 Update.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has applied with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat Rett Syndrome, a rare genetic neurological disorder.

NTT Research, Inc., a division of NTT (TYO:9432), today announced plans to hold Upgrade 2023, the NTT Research Summit, as an in-person event on March 15-16, 2023.

Eisai announced today the presentation of research across various types of gastrointestinal cancers during the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI23), which is taking place in-person in San Francisco, California and virtually from January 19-21.

enVVeno Medical Corporation today announced the promotion of Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer.

Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EXG102-031.

Boekel Scientific introduces two new items to help enhance histology and anatomical pathology laboratories: a new Large Wax Dispenser and a Microscope Slide Storage Cabinet Wheeled Base Dolly.

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include four new indications for its PD-1 inhibitor tislelizumab. KYPROLIS® (carfilzomib), a proteosome inhibitor licensed-in from Amgen.